[go: up one dir, main page]

NO991655L - FremgangsmÕte for Õ inhibere stress-aktiverte-proteinkinaser - Google Patents

FremgangsmÕte for Õ inhibere stress-aktiverte-proteinkinaser

Info

Publication number
NO991655L
NO991655L NO991655A NO991655A NO991655L NO 991655 L NO991655 L NO 991655L NO 991655 A NO991655 A NO 991655A NO 991655 A NO991655 A NO 991655A NO 991655 L NO991655 L NO 991655L
Authority
NO
Norway
Prior art keywords
protein kinases
activated protein
inhibiting stress
inhibiting
stress
Prior art date
Application number
NO991655A
Other languages
English (en)
Other versions
NO991655D0 (no
Inventor
Xinkang Wang
Tian-Li Yue
Original Assignee
Boehringer Mannheim Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Pharm Corp filed Critical Boehringer Mannheim Pharm Corp
Publication of NO991655D0 publication Critical patent/NO991655D0/no
Publication of NO991655L publication Critical patent/NO991655L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
NO991655A 1996-10-09 1999-04-08 FremgangsmÕte for Õ inhibere stress-aktiverte-proteinkinaser NO991655L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2845996P 1996-10-09 1996-10-09
PCT/US1997/018272 WO1998015272A1 (en) 1996-10-09 1997-10-09 Method for inhibiting stress-activated protein kinases

Publications (2)

Publication Number Publication Date
NO991655D0 NO991655D0 (no) 1999-04-08
NO991655L true NO991655L (no) 1999-06-08

Family

ID=21843560

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991655A NO991655L (no) 1996-10-09 1999-04-08 FremgangsmÕte for Õ inhibere stress-aktiverte-proteinkinaser

Country Status (16)

Country Link
US (1) US6214854B1 (no)
EP (1) EP0946172A4 (no)
JP (1) JP2002512591A (no)
KR (1) KR20000048967A (no)
CN (1) CN1157188C (no)
AU (1) AU4751897A (no)
BR (1) BR9712283A (no)
CA (1) CA2267967A1 (no)
CZ (1) CZ123099A3 (no)
IL (1) IL129326A0 (no)
NO (1) NO991655L (no)
NZ (1) NZ335080A (no)
PL (1) PL332638A1 (no)
TR (1) TR199900762T2 (no)
WO (1) WO1998015272A1 (no)
ZA (1) ZA979055B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041767A1 (en) * 1999-12-07 2001-06-14 Duke University USE OF α1AR SUBTYPE-SELECTIVE DRUGS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20050148779A1 (en) * 2002-04-30 2005-07-07 Wei Chen Carvedilol monocitrate monohydrate
AU2003251627A1 (en) * 2002-06-27 2004-01-19 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
EP1534270A4 (en) * 2002-06-27 2006-05-17 Sb Pharmco Inc CARVEDILOL PHOSPHATE SALTS AND / OR ITS SOLVENTS, CORRESPONDING COMPOSITIONS AND / OR TREATMENT PROCEDURES
CN101039957A (zh) 2003-05-16 2007-09-19 因特缪恩公司 合成的趋化因子受体配体及其使用方法
RS54573B1 (sr) 2003-10-14 2016-06-30 F. Hoffmann-La Roche Ltd Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
JP5072364B2 (ja) * 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法
WO2005051383A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
KR20070085227A (ko) * 2004-08-09 2007-08-27 앨리오스 바이오파마 인크. 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US12091408B2 (en) * 2013-08-30 2024-09-17 Uti Limited Partnership Store overload-induced calcium release inhibitors and methods for producing and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5405863A (en) 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
US5308862A (en) 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies

Also Published As

Publication number Publication date
CA2267967A1 (en) 1998-04-16
EP0946172A1 (en) 1999-10-06
US6214854B1 (en) 2001-04-10
KR20000048967A (ko) 2000-07-25
TR199900762T2 (xx) 1999-07-21
NZ335080A (en) 2000-04-28
NO991655D0 (no) 1999-04-08
CN1239888A (zh) 1999-12-29
EP0946172A4 (en) 2002-05-22
WO1998015272A1 (en) 1998-04-16
AU4751897A (en) 1998-05-05
IL129326A0 (en) 2000-02-17
PL332638A1 (en) 1999-09-27
CN1157188C (zh) 2004-07-14
JP2002512591A (ja) 2002-04-23
WO1998015272A8 (en) 2000-03-23
ZA979055B (en) 1999-05-10
BR9712283A (pt) 1999-08-31
CZ123099A3 (cs) 1999-11-17

Similar Documents

Publication Publication Date Title
CY2008015I2 (el) Δικυκλικες ετepοαρωματικες ενωσεις σαν αναστολεις πρωτεϊνης κινασης τυροσινης
DK0806474T3 (da) Fremgangsmåde til at stabilisere drikkevarer
DE69739418D1 (de) System zur Herstimulussteuerung
NO20001748L (no) FremgangsmÕte for Õ modulere serin/treonin proteinkinasefunksjon med 5-azaquinoksalin-baserte forbindelser
EP0891350A4 (en) INHIBIOTS OF FARNESYL PROTEIN TRANSFERASE
NO983405L (no) Fremgangsmåte for ökning av smöreevnen til snöskigrunnflater
NO983892D0 (no) Inhibitorer for farnesyl-proteintransferase
PT927183E (pt) Inibidores espirociclicos de metaloproteases
NO20010117D0 (no) Fremgangsmåte for behandling av sövnlöshet
NO991655D0 (no) FremgangsmÕte for Õ inhibere stress-aktiverte-proteinkinaser
EP0904080A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
ATE205836T1 (de) Bicyclische 4-aralkylaminopyrimidin-derivate als tyrosinkinase-inhibitoren
FI951514A7 (fi) Uusia mono- ja bisyklisiä DNA-gyraasiinhibiittoreita
DE69700801D1 (de) Verfahren zur Kopositionierung von Satelliten
DK0987356T3 (da) Fremgangsmåde til trækning
DE69737237D1 (de) Verfahren zur trockenätzung
EP0891353A4 (en) FARNESYL PROTEIN TRANSFERASE INHIBITORS
IT1283794B1 (it) Metodo per la rimozione di acqua da superfici
FI960534L (fi) Menetelmä analyyttien ei-kilpailevaa määritystä varten
EP0959883A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
DK0912446T3 (da) Fremgangsmåde til behandling af vand
ATE218559T1 (de) Verfahren zur monoacylierung von hydroxytaxanen
MD676F1 (ro) Metoda de tratament al rinosinuzitelor Method for treatment of the rhinosinusitis
UA25728A (uk) Спосіб одержаhhя сорбеhту для очистки меляси
IT1294014B1 (it) Metodo di applicazione per fangoterapia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application